Prodotti competitors / Area HIV
Trial update - Brii Biosciences: BRII-732 as part of an oral QW regimen for HIV treatment and PrEP
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
Brii Biosciences published a clinical development update in which it announced the discontinuation of BRII-778, a RPV long-acting reformulation, citing the Ph1 PK data presented at IDWeek 2022 to support this decision (12/27).
-
- The company also highlighted that development of BRII-732, an ISL prodrug, will continue to explore lower oral doses following the lift of its clinical hold.
- Brii now intends to explore partnership opportunities to continue development of BRII-732 as part of an oral QW regimen for HIV treatment and PrEP
Additional information to the following link: https://www.biospace.com/article/brii-biosciences-provides-update-on-strategic-clinical-development-progress-december-27-2022/
Grazie per il tuo feedback!